Dr. Lakshmi Chandra Mishra
M. Pharm., Ph.D. (Pharmacology), B.I.M.S. (Ayurvedic Physician)
National Center for Ayurveda and Toxicology Reviews
13505 Cleveland Dr. Rockville, MD 20850
301 762 82632; 301 537 8804; mishra13505@yahoo.com; www.lcmishra.com; www.aapra.com
Dr. Lakshmi C. Mishra is Director of National Center for Ayurveda and Toxicology Reviews, Rockville MD since April 2003. He provides education information about Ayurvedic health care. He is also working for CECON group of New York as a pharmacologist, toxicologist and research consultant to plan safety and efficacy studies and evaluate safety and efficacy clinical trial data on dietary supplements, drugs, and chemicals for US FDA and US EPA registration and labeling requirements.
Dr. Lakshmi C. Mishra was Adjunct Professor in the Research Division (1998-2003), provided clinical Ayurvedic services in the SCU health system; the first ayurvedic health care in the SCU clinic system. He has a long work history as a toxicologist for the federal government, has specialized in carcinogenesis and cancer chemotherapy research in the past (1974-1997), and has turned his attention to the development of treatment protocols combining Western Science and Ayurvedic principles. He provided the content expertise for the development and implementation of basic science, cancer chemotherapy and chemo-prevention using herbal dietary supplements. Dr. L.C. Mishra was PI of trials using animal models to investigate both guggul and another Ayurvedic herb, Ashwagandha.
He has an extensive background, both as a clinician in modern and Ayurvedic medicine and as a bench scientist in cancer chemotherapy, pharmacology and toxicology, a unique combination of qualifications indeed. He has been a reviewer for Alternative Therapies in Health and Medicine (ATHM) particularly in the areas of cancer chemotherapy, pharmacology, toxicology, Ayurvedic herbal therapies. He was an advisor to RAND Corporation (2000-01), Los Angeles, California for a systematic review of Ayurvedic therapies for a specific diagnosis, funded by AHRQ, P.I., Ian Coulter. He was also a member of the editorial board for Journal of American Nutraceutical Association till Spring 2002. His other interest includes osteoarthritis and autoimmune diseases, e.g., rheumatoid arthritis. He has collaborated with the University of Southern California, School of Pharmacy to study the effects of Guggul and Ashwagandha in protecting oxidative DNA fragmentation in rat brain in a stroke rat model.
Dr. Mishra has 23 years of experience in the field of public health policy and health related safety regulations with Federal Government agencies. He had been an Ex-officio Board Member of the National Cancer Advisory Board, National Cancer Institute, National Institutes of Health, Bethesda, MD for 16 years (US CPSC representative, Jan 1981 to November 3, 1997). The board is appointed by the President of the US as mandated by the US congress. It oversees the National Cancer Research Program.
Recently, he edited a book, “Scientific Basis of Ayurvedic Therapies” CRC press 2003. The book consists of 625 pages and over 3000 references of recent scientific publications on ayurvedic herbs.
Scientific milestones
I. Cancer chemotherapy
1.Oncogeneic viruses: He demonstrated with Rauscher virus that oncogneic viruses do not have to be in a intact particle form and that soluble material in the 80,000g supernatant is just as potent as the particulate material in inducing leukemia in mice. The active material is probably a ribonucleoprotein. Using the supernatant he developed a spontaneous tumor model to test cancer chemotherapeutic agents and screened many antitumor agents.
2.Delayed toxicity: Delayed toxicity in tumor bearing rats appearing 60 days after the first 2-5 doses of anti-folic acid compounds containing alkylating moiety was thought for many years to be due to irreversible blockade of folic acid recepters because rats were showing signs of folic acid deficiency and dying due to severe anemia. Folinic acid administration helped but did not reverse the toxicity. Dr. Mishra demonstrated that the fast growing cells (blast cells) of the teeth were damaged by the initial drug treatment thus the teeth became weak and broke off in next 60 days. As a consequence the rats could not bite and eat regular food and died due to starvation. When the rats were given powdered food orally twice a day, all rats showing delayed toxicity recovered and lived their normal lifespan. His study established the mechanism of the delayed toxicity.
3. Rational design of anticancer drugs: He demonstrated the feasibility of enzyme-dependent lethal synthesis concept to develop drugs with a high degree of selectivity. He used cancer cells resistant to an antitumor agent, methotrexate (inhibitor of dihydrofolate reductase enzyme), containing higher levels of dihydrofolate reductase enzyme and treated them with dihydrohomofolic acid and showed that the tetrahydrohomofolic acid formed in the cells was selectively toxic to cancer cells. This was well documented in L1210 leukemia tumor bearing mice. A US patent was granted to National Cancer Institute in 1974 on 5-methyl tetrahydrohomofolate based on Dr. Mishra’s research; an example of rational drug development where he carried a chemical molecule to an important anti-cancer drug.
4.In-vivo enzyme assay: Dr. Mishra has worked extensively with chromatographic techniques conducting biochemical studies using dihydrofolate reductase and pioneering the in-vivo bioassay of dihydrofolate reductase enzyme to determine the enzyme inhibition. He also developed analytical methods to conduct drug metabolism and tissue distribution studies on dihydro- and tetrahydrohomofolate.
II. Carcinogenesis and Toxicological studies
1. Cancer guidelines: He developed guidelines to assess carcinogenic potential of chemicals for U.S. Consumer Products Safety Commission to regulate cancer causing chemicals in consumer products (191-92).
2.Neurotoxicity: He also developed guidelines to assess carcinogenic potential of chemicals for U.S. Consumer Products Safety Commission to regulate cancer causing chemicals in consumer products (1991-92).
2.Toxicology and health risk assessment: Dr. Mishra evaluated over 50 pesticides and many solvents and chemicals for health risk for US Environmental agency and US Consumer Product Safety commission.
III.Complementary Alternative Medicine: Ayurveda
One of the research goals of Dr. Mishra has been to explore scientific basis for ayurvedic therapies. He conducted a major review of pharmacological studies on Commiphora mukul an ayurvedic herbs proven highly effective in musculoskeltal diseases and cholesterol lowering effects. He further reviewed scientific data on Withania somnifera for adaptogenic properties and its use in stress and mental disorders. In addition, he initiated the clinical trials and case studies on ayurvedic therapies for musculoskeletal disease, e.g., osteoarthritis, TMJ, and fibromyelgia. His extensive literature review on ayurvedic therapies led him to write a book entitled Scientific Basis of Ayurvedic Therapies, published by CRC Press in 2003. The book consists of 625 pages and over 3000 references of recent scientific publications on ayurvedic herbs. It provides comprehensive information on research on ayurvedic therapies for 26 diseases along with six chapters on basic concepts of therapies, Panchakarma, Research Design, status of Ayurveda in India and Bhasmas. The book can be viewed at www.amazon.com or www.redwingbooks.com/products/books/sciBasAyuThe.cfm . In addition he has published 19 articles on ayurvedic therapies. He also started Ayurvedic Health Care Services in the Southern California University Health Care System.
Dr. Mishra has given many guest lectures at universities, societies as well as temples and churches.
1. Historical Perspective of Ayurveda, River Road Unitarian Church, Bethesda MD, 1/2/05
2. Ayurvedic Therapies of Rheumatoid Arthritis, Integrated Medicine Educational Program: Integrating Ayurveda into Clinical Practice. Orlando Florida, September 17 - 19, 2004
3. Durga Temple: He is providing Ayurvedic Health Care services at the temple every 2nd Sunday of the month. He also gives lecture on a variety of health issues and diseases. 2004
2.Ayurvedic Therapies of Rheumatoid Arthritis, Integrated Medicine Educational Program: Integrating Ayurveda into Clinical Practice. Orlando Florida, September 17 - 19, 2004
2.Ayurvedic Health Care lecture at La Mirada Adults Activity Center, La Mirada CA 90638, 2003
2.Regular lectures every semester on Ayurveda to chiropractic students at Southern California University (1998-2003)
7. Ayurvedic Therapies at School of Pharmacy USC, California, Fall 02
8. Ayurvedic Therapies at Southern California University of Health Sciences July, 2001
9. Historical Perspective of Ayurveda: Introduction to Ayurvedic herbs, their purity and analysis. Southern California University of Health Sciences , 8/16/00
10. 3rd. Southern Yoga Conference, Houston Texas: Scientific Basis and Chemistry of guggul 11/2/00
11.Introduction to Ayurvedic Concepts of Illness and Therapy, University of California Medical School at Irvine, 1/19/99
11.Scientific Basis of Ayurvedic Therapies; Chemistry and Use of Guggul, University of California Los Angeles, Dietary Supplement Center 1/18/00
11. Continuing Education Program on Internet: ATHM, 2000 Etiology and Management of Mental Depression according to Ayurved, the Traditional Medical System of India, 9/22/00
Joint authorship lectures and presentations
1. Vinjamury SP, Singh BB, Mishra LC, Khorsan R, Comberiati R, Meier M, Holm S. Effectiveness of pragmatic chiropractic treatment in temporomandibular disorders (TMD)- A pilot study. Paper submitted and accepted for platform presentation at ACC Conference at Las Vegas, 2005
2. Vinjamury SP, Singh BB, Mishra LC, Khorsan R, Comberiati R, Meier M, Holm S. Effectiveness of pragmatic chiropractic treatment in temporomandibular disorders (TMD)- A pilot study. Paper submitted and accepted for platform presentation at ACC Conference at Las Vegas, 2005
3. Singh, B.B., Mishra, L.C., Gandhi S, Khorsan, R., Singh, V.J., Vinjamury, S.P, Kizhakkeveettil, A. Ayurvedic and Collateral Herbal Treatments of Liver Diseases: A Systematic Review of Randomized Control Trials (RCTs) and Quasi-Experimental Designs (QEDs), NAMA Conference, Long Beach, CA., 10/22/04
4. Singh, B.B., Mishra, L.C., Vinjamury, S.P, Khorsen, R., Nanjegowda, D., Kubik, E., Shepard, N. Effectiveness of Pragmatic Ayurvedic Care on the Treatment of Osteoarthritis (OA): An Experimental Case Series, WAVE Conference, Shady Grove, MD., 7/04.
5. Singh, B.B., Mishra, L.C., Vinjamury, S.P., Aquilina, N., Singh, V.J., Shepard, N. The Effectiveness of Commiphora Mukul for Osteoarthritis (OA) of the Knee: An Outcomes Study, WAVE Conference, Shady Grove, MD., 7/04.
6. Singh, B.B., Mishra, L.C., Vinjamury, S.P., Kubik, E., Singh, V.J., Shepard, N. Ayurvedic Herbal Treatments of Hyperlipidemia: A Systematic Review, WAVE Conference, Shady Grove, MD., 7/04.
7. Mishra, L.C., Singh, B.B. Ayurvedic Therapies of Ama-Vata (Rheumatoid Arthritis), AAPI Conference, San Diego, CA., 6/04. Mishra, L.C., Singh, B.B. Ayurvedic Therapies of Ama-Vata (Rheumatoid Arthritis), AAPI Conference, San Diego, CA., 6/04.
8. Singh, B.B., Mishra, L.C., Vinjamury, S., Aquilina, N., Singh, V., Shepard, N. The Effectiveness of Commiphora Mukul for Osteoarthritis of the Knee: An Outcomes Study, RAC Conference, New Orleans, LA. (3/2003).
9. Vinjamury, S.P., Singh, B.B., Mishra, L.C. Research Issues in Complementary and Alternative Medicine. Presented at the World Ayurveda Congress, Kochi, Kerala, India, (11/2002).
10. Singh, B.B., Mishra, L.C. Effectiveness of Guggul in Treatment of Osteoarthritis. Findings from an Experimental Case Study and an Outcomes Study. Presented to SCU Clinical Faculty, (3/2002).
11. Singh, B.B., Mishra, L.C. Ayurved as an Adjunctive Therapy to Chiropractic Care: Evidence of Effectiveness in OA. SCUHS Visiting Scholar Program, (3/2002).
Society Membership
American Association of Cancer Research, 1968 to 1985
American Society of Pharmacology and Experimental Therapeutics, 1967-1985
Media Appearances
Guest on a talk show two times on Ayurved on Adelphia Cable Television Net Work in the Southern California area, 7/26/01 and 11/20/02.
Guest on a talk show WETA-Darshan TV, 4/13/04.
1.Scientific Basis of Ayurvedic Therapies, Lakshmi Chandra Mishra, Editor, CRC Press, 2003
2.Mishra, L.C., Health Care and Disease Management in Scientific Basis of Ayurvedic Therapies, Lakshmi Chandra Mishra, Editor, chapter 2, CRC Press, 2003
3.Mishra, L.C., Rheumatoid Arthritis, Osteoarthritis, and gout in Scientific Basis of Ayurvedic Therapies, Lakshmi Chandra Mishra, Editor, chapter 10, CRC Press, 2003
4.Mishra, L.C., Allergic Reactions in Scientific Basis of Ayurvedic Therapies, Lakshmi Chandra Mishra, Editor, chapter 12, CRC Press, 2003
5.Sahu, M. & Mishra, L.C., Benign growth, Cysts, and Malignant Tumors in Scientific Basis of Ayurvedic Therapies, Lakshmi Chandra Mishra, Editor, chapter 16, CRC Press, 2003
6.Vohra, D.S. & Mishra, L.C., Alzheimer’s Disease in Scientific Basis of Ayurvedic Therapies, Lakshmi Chandra Mishra, Editor, chapter 23, CRC Press, 2003
7.Singh, R.H., Mishra & L.C., Psychiatric Disorders in Scientific Basis of Ayurvedic Therapies, Lakshmi Chandra Mishra, Editor, chapter 25, CRC Press, 2003
8.Mishra, L.C. & Singh R.H., Parkinsons’s Disease in Scientific Basis of Ayurvedic Therapies, Lakshmi Chandra Mishra, Editor, chapter 26, CRC Press, 2003
9.Gauthaman, K., & Mishra, L.C., Ischemic Heart Disease in in Scientific Basis of Ayurvedic Therapies, Lakshmi Chandra Mishra, Editor, chapter 30, CRC Press, 2003
10.Singh, B. B., Mishra, L. C., Vinjamury, S. P., Aquilina, N., Singh, V. J., Shepard, N., The effectiveness of Commiphora mukul for osteoarthritis of the knee: An outcome study. , Alt. Ther. Health & Med. 9 (3): 74, 02
11.Adams, J., Klaidman, L. K., Mishra, L. C., Singh, B. B., Effect of Guggul in rat model of stroke. , Alt. Ther. Health & Med. 8 (4): 20, 02
12.James D. Adams, Jr.,1 Jun Yang,1 Lakshmi C. Mishra2 and Betsy B. Singh. Effects
of Ashwagandha in a stroke model, Alt. Ther. Health & Med. 8 (5): 18, 02
13.L.C. Mishra, B.B. Singh, and S. Dagenais. Ayurved: Historic Perspective and Principles of the Traditional Health Care System of India. Alt. Ther. Health & Med. 7(2): 36-41, 2001
14.L.C. Mishra, B.B. Singh, and S. Dagenais. Health Care and Disease Management in Ayurved. Alt. Ther. Health & Med. 7(2): 44-50, 2001
15.B.B. Singh, N. Aquilina, L.C. Mishra, F. Kohlbeck. The Usefulness of Commiphora Mukul for Osteoarthritis of the Knee: An Experimental Case Study. Alt. Ther Health & Med. 7(2): 120 & 112-114, 2001
16.B.B. Singh, F. Zarow, L.C. Mishra, S. Dagenais Acupuncture as a Treatment for Osteoarthritis of the Knee: Clinical Relevance. Topics in Clinical Chiropractic7(2): 1-4, 2000
17.L.C. Mishra, B.B. Singh, and S. Dagenais. Ayurvedic Therapies of Arthritis. Topics in Clinical Chiropractic 7(2): 13-16, 2000
18. L.C. Mishra, B.B. Singh. Scientific Basis for Therapeutic Uses of Guggul (Commiphora Mukul). Topics in Clinical Chiropractic, 7 (2) :51-56, 2000
19. L.C. Mishra, B.B. Singh, and S. Dagenais. Scientific Basis for Therapeutic Uses of Ashwagandha (Withania somnifera). Alt. Med. Review, 5 (4): 334-346, 2000
Ph.D. in Biochemical Pharmacology; State University of N.Y. at Buffalo
M. Pharm. (Pharmacognosy of Ayurvedic herbs), Banaras Hindu University, Varanasi, U.P. India
B. Pharm., Banaras Hindu University, Varanasi, U.P. India
BIMS (Bachelor of Indian Medicine and Surgery), Bundalkhand Ayurvedic College, Jhansi, U.P. India. (Integrated System of Modern and Ayurvedic Medicine, a 5-year program, developed by the Government of India and is equivalent to the American M.D.)
Associate Contract Management and Project Supervising Scientists and Engineers from Office of Personnel Management
Health Science Administrator/Grants - GS-14 rating from NIH
1983 Introduction to Supervision Course given by the U.S. Office of Personnel Management
Contract Management for Project Officers, US C.P.S.C.
Work Experience
Member of the editorial board for JANA (Journal of the American Neutraceutical Association
Member of the Editorial Review Panel, Alternative Therapies in Health and Medicine, A peer reviewed journal.
1998, September- Present, Adjunct Professor [full], Southern California University of Health Sciences, Whittier, CA
-Provide leadership to design and implement clinical and basic science investigations of commonly used herbal therapies, to evaluate the financial implications of their use, and to provide elective courses to pre-clinical and clinical students when required.
-Provide leadership in publication of literature on Ayurvedic Medicine.
-Review research manuscripts for peer reviewed journals. Currently reviewing manuscripts for Alternative Therapies in Health and Medicine.
-Filed an RO1 as PI in June, 1999 to NCCAM/NIH to evaluate an Ayurvedic herb for arthritis; submissions of one R21 project are planned for Feb.2001 on an Ayurvedic herb for antistress and anti-oxidant properties.
-Advisor to RAND Corporation, Los Angeles California,
1997 – present Sequoia Communications & Health Sciences, Inc, Rockville, MD; Director of Health Sciences.
Provide consultant service to a variety of food, pharmaceutical, and research organizations in the area of analytical methods, toxicology, pharmacology and health risk assessment.
Research and teaching in Ayurvedic herbal dietary supplements.
U.S. Consumer Products Safety Commission
Bethesda, MD.
Senior Toxicologist - Duties included work on cancer risk assessment from suspect carcinogens and health risk from neurotoxic chemicals. Major contribution was developing the guidelines to evaluate cancer causing chemicals and neurotoxic chemicals (Federal Register, 57:46626‑‑74, 1992).
Branch Chief - Supervised toxicity reviews and provided recommendations to the Agency concerning health effects of many chemicals. Supervised the work of six other scientists.
Toxicologist - - Duties included work on cancer risk assessment from suspect carcinogens and health risk from neurotoxic chemicals.
Toxicologist, Environmental Protection Agency
Washington D.C.
Duties included work on pesticide residues in food and cancer risk assessment from chemical. Published a paper regarding metabolism of pesticides in August 1976. As a Pharmacologist at the U.S.EPA, involvement included evaluation of pesticide residue in food safety for general toxicity, immunotoxicity, neurotoxicity, mutagenicity, carcinogenicity, and teratogenicity. Conducted health risk assessment and health review on several toxic chemicals.
Microbiological Associates, Bethesda, MD
Duties included work on Cancer chemotherapy under a contract with the National Cancer Institute. Served as Branch Chief at Microbiological Associates Inc., Bethesda, MD. supervising the evaluation of homofolate type antifolates for their antitumor activity, developed in‑vivo enzyme assay for dihydrofolate reductase, generated evidence for enzyme‑dependent lethal synthesis concept to develop new chemotherapeutic agents. Conducted research on analytical methods to study metabolism and tissue distribution studies on some alkylating agents and antifolates. Twenty eight papers were published on antifolates, homofolates and other anticancer agents. I developed a new in-vivo enzyme assay, and several other analytical methods during my tenure.
Roswell Park Memorial Medical Park
Buffalo, NY
Duties included research work in cancer chemotherapy (antifolates).
Lady Harding Medical College
New Delhi, India; Professor of Pharmacology- Duties included teaching pharmacology and pharmacy, and supervision of the hospital pharmacy
Maulana Azad Medical College, New Delhi, India; Professor of Pharmacology- Duties included teaching pharmacology and pharmacy, and supervision of the hospital pharmacy.
Hindustan Antibiotics Manufacturing Company
Puna, Maharastra, India; Scientist/Quality Control Supervisor - Duties included work on quality control related analysis of streptomycine and penicillin.
Honors
Received cash merit award in 1992 from the US CPSC
CPSC representative (ex-officio) Board Member for the National Cancer Advisory Board, National Cancer Institute, National Institutes of Health, Bethesda, MD, Jan 1981- November 3, 1997.
1. L.C. Mishra, Phytochemical Investigations on Justicia Gendarusa ( an ayurvedic drug). M. Pharm. Thesis, Banaras Hindu University, Banaras, India 1959.
2.L. C. Mishra, Pharmacologic Studies of Some Alkylating Agents. Ph.D., Thesis, State University of New York at Buffalo, June 1967.
3.P. Hebborn, L. C. Mishra, C. Dalton and J. P. G. Williams. Dental Lesions in Rats Induced by Radiomimetic Agents. Arch. Path., 80: 110‑115, 1965.
4.L. C. Mishra, F. Rosen and C. A. Nichol. Studies Designed to Overcome the Resistance of Walker Carcinoma 256 (W‑256) to Amethopterin. Proc. Am. Assoc. Cancer Res., 8: 47, 1967.
5.C. A. Nichol, F. Rosen, L. C. Mishra and W. Werkheiser. Comparison of Drug Sensitive and Refractory Solid Tumors. 5th Intl. Congress of Chemotherapy, Vienna, 1967.
6.L. C. Mishra, F. Rosen and C. A. Nichol. Uptake of 2,4‑ Diamino‑5‑ (3'‑4'‑dichlorophenyl)‑6‑methyl pyrimidine (DDMP) and Amethopterin by Tumors and Normal Tissues. Proc. Am. Asso. Cancer Res., 9: 49, 1968.
7.L. C. Mishra and J. A. R. Mead. Tissue Distribution of Tetrahydrohomofolic Acid in Mice. Fed. Proc. 27: 659, 1968.
8.L. C. Mishra and J. A. R. Mead. Effect of Tetrahydro‑ homofolic Acid (NSC‑89,473) on the Biosynthesis of Nucleic Acids in Leukemic Mice. Proc. Am. Asso. Cancer Res., 10: 1969.
9.L. C. Mishra and A. S. Parmar. Studies on Stability of Tetrahydrohomofolic Acid (NSC‑89,473) in Mice. Fed. Proc. 28: 445. 1969.
10.L. C. Mishra and J. A. R. Mead. Tissue Distribution of Tetrahydrohomofolic Acid in Mice. Cancer Res. 30: 642‑ 649, 1970.
11.L. C. Mishra, A. S. Parmar and J. A. R. Mead. The Anti‑ leukemic Activity of Dihydrohomofolate (H2HF) and its Reduction to Tetrahydrohomofolate (H4HF) in Mice. Proc. Am. Asso. Cancer Res., 11: 57, 1970.
12.L. C. Mishra, A. S. Parmar and J. A. R. Mead. The Effect of Pretreatment with Methotrexate on the Reduction of Dihydrohomofolic Acid in Mice. Biochem. Pharmacol. 20: 2871, 1971.
13.L. C. Mishra and J. A. R. Mead. Effect of Tetrahydro‑homofolic Acid on DNA Biosynthesis in Leukemic Mice. Proc. Soc. Exptl. Biol. & Med. 138: 709‑711, 1971.
14.L. C. Mishra, A. S. Parmar and J. A. R. Mead. Chemical Transformations of Tetrahydrohomofolic Acid In Vitro and In Vivo. Chem.‑Biol. Interactions. 4: 97‑102, 1971‑72.
15.L. C. Mishra and J. A. R. Mead. On the Biochemical Mechanism of Action of Tetrahydrohomofolic Acid. Biochem. Pharmacol. 21: 579‑581, 1972.
16.L. C. Mishra and P. Hebborn. Ultrafiltration Studies on Mouse Plasma Containing Rauscher Virus. Life Sciences 10: 1375‑1380, 1971.
17.L. C. Mishra and J.A.R. Mead. Further Evaluation of the Antitumor Activity of Homofolate and its Reduced Derivatives. Chemotherapy 17: 283‑292, 1972.
18.L. C. Mishra and J.A.R. Mead. Uptake and Physiological Disposition of 1‑acetyl 2‑picolinoyl hydrazine (NSC 68626) in Rats bearing Walker Carcinoma 256. Cancer Research, 33:2393-7
19.L. C. Mishra, A. S. Parmar and J.A.R. Mead. Assessment of Dihydrofolate Reductase (H2F‑R) Activity in Vivo after Administration of 3H‑dihydrofolate. The Pharmacologist, 13: 208, 1971.
20.L.C. Mishra, A.S. Parmar and J.A.R. Mead. A Method to Assess Dihydrofolate‑reductase Inhibition in vivo. Analytical Biochemistry, 48: 515‑523, 1972.
21.L.C. Mishra, A.S. Parmar and J.A.R. Mead. Comparative Antitumor Activity of 5‑Methyl‑Tetrahydrohomofolate (CH3‑ H4HF) and Tetrahydrohomofolate (H4HF) in Mice. Proc. Am. Asso. Cancer Res., 13: 76, 1972.
22.L. C. Mishra, A. S. Parmar and J. A. R. Mead. Enzymic Synthesis of Tetrahydrohomofolate: Possible Basis for Antitumor Activity. 5th Int. Congress on Pharmacology, Abstract # 952, 159, 1972.
23.L. C. Mishra and P. Hebborn. Peripheral Nucleated Cell Count as a Method of Assessing the Response of antileukemic Agents in Rauscher Virus‑diseased Mice. Oncology 27: 234‑243, 1973.
24.L.C. Mishra and J. A. R. Mead. Uptake and Physiological Disposition of Dihydrohomofolate (DHF) to Tetrahydrohomofolate (THF) and its Physiological Disposition in Rhesus Monkeys. Fed. Proc. 32: 777, 1973.
25.L. C. Mishra, A. S. Parmar and J.A.R. Mead. Inhibition of Dihydrofolate Reductase by Methotrexate (M) in Vivo: Dose‑effect Relationship in Tumor‑bearing Mice. Proc. Am. Asso. Cancer Res., 14: 72, 1973.
26.L. C. Mishra, A. S. Parmar and J. A. R. Mead. Physiological Disposition of Dihydrohomofolate in Mice Bearing MTX‑sensitive and‑resistant Tumors. Proc. Am. Assoc. Cancer Res. 15: 113, 1974.
27.L. C. Mishra, A. S. Parmar and J. A. R. Mead. Regeneration of Tetrahydrohomofolate in Cells. Biochem. Pharmacol. 23: 1827‑1834, 1974.
28.L. C. Mishra, A. S. Parmar and J. A. R. Mead. Reduction and Metabolism of Dyhydrohomofolate in Rhesus Monkeys. Cancer Res. 34: 3187‑3191, 1974.
29.A. E. Auletta, A. M. Gery, J. R. Davis, L. C. Mishra, J.A. R. Mead. Effect of Folate Analog upon Biochemical events in the Normal Mouse Kidney. Life Sciences, 14: 1541‑1553, 1974.
30.L. C. Mishra. Metabolism Studies of Pesticides in Large Animals: Regulatory consideration. In the symposium entitled "Pesticide Metabolism in Large Animals," organized by Am. Chem. Soc. San Francisco, August 29 ‑ September 3, 1976. In "Fate of Pesticides in Large Animals "Edited By G.W. Ivie and H.W. Dorough. Academic Press p. 47‑51, 1977.
31.L.C. Mishra. Criteria for Classifying Carcinogens in Consumer Products for Purpose of Labeling under the Federal Hazardous Substances Act. Labeling Requirements for Art Materials and Other Products; Final Rules. 16 CFR Part 1500, Federal Register/ Vol. 57. No. 197/Friday, October 8 1992, Carcinogenicity. p. 46632-37.
32. L.C. Mishra. Same title as in 36 Neurotoxicity, p 466637-41